期刊
JOURNAL OF NUCLEAR MEDICINE
卷 62, 期 6, 页码 829-832出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.120.251579
关键词
Cu-64; Cu-67; theranostics; prostate cancer; prostate-specific membrane antigen
资金
- sas
- Clarity Pharmaceuticals
- Victorian Cancer Council
67Cu-CuSarbisPSMA demonstrates therapeutic potential in a PSMA-expressing model of prostate cancer, with the ability to inhibit tumor growth and improve survival rates.
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine-ureido-glutamate groups. Here, we report the therapeutic potential of 67Cu-CuSarbisPSMA. Methods: Growth of PSMA-positive xenografts was evaluated after treatment with 67Cu-CuSarbisPSMA or 177Lu-LuPSMA imaging and therapy (I&T). Results: At 13 d after injection, tumor growth was similarly inhibited by the 2 tracers in a dose-dependent manner. Survival was comparable after single (30 MBq) or fractionated (2 center dot 15 MBq, 2 wk apart) administrations. Conclusion: 67Cu-CuSarbisPSMA is efficacious in a PSMA-expressing model of prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据